Figure 4. Overall Survival of Patients With Metastatic Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors (ICIs) vs Non-ICIs by Programmed Death Ligand 1 (PD-L1) Status.
The diamonds indicate the pooled estimates, derived from the generic inverse variance (IV) and a random-effects model. Durva indicates durvalumab; HR, hazard ratio; and Treme, tremelimumab.